Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy

Experimental Neurology

Volumn 238, Issue 2, 2012, Pages 225-234

  Zheng, H ^a   Xiao, W H ^a,b   Bennett, G J ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Acetyl l carnitine; Chemotherapy neuropathy; Proteasome inhibitor; Sensory neuropathy

Indexed keywords

ADENOSINE TRIPHOSPHATE; BORTEZOMIB; LEVACECARNINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE);

ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL PROTECTION; CHRONIC PAIN; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; MALE; MITOCHONDRIAL RESPIRATION; MITOTOXICITY; NERVE FIBER; NEUROPATHIC PAIN; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SYNTHESIS; RAT; SCHWANN CELL; SCIATIC NERVE; TOXICITY;

ACETYLCARNITINE; ACTIVATING TRANSCRIPTION FACTOR 3; ADENOSINE TRIPHOSPHATE; ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; AXONS; BORONIC ACIDS; CITRATE (SI)-SYNTHASE; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT COMPLEX II; GANGLIA, SPINAL; HYPERALGESIA; MALE; MITOCHONDRIA; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; SCHWANN CELLS; SCIATIC NERVE; TIME FACTORS; UBIQUITIN THIOLESTERASE;

EID: 84866650587     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.08.023     Document Type: Article

References (61)

1. Argyriou A.A., Iconomou G., Kalofonos H.P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008, 112:1593-1599.
2. Argyriou A.A., Bruna J., Marmiroli P., Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit. Rev. Oncol. Hematol. 2012, 82:51-77.
3. Bennett G.J., Liu G.K., Xiao W.H., Jin H.W., Siau C. Terminal arbor degeneration (TAD): a novel lesion produced by the antineoplastic agent, paclitaxel. Eur. J. Neurosci. 2011, 33:1667-1676.
4. Boyette-Davis J., Dougherty P.M. Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. Exp. Neurol. 2011, 229:353-357.
5. Boyette-Davis J.A., Cata J.P., Zhang H., Driver L.C., Wendelschafer-Crabb G., Kennedy W.R., Dougherty P.M. Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. J. Pain 2011, 12:1017-1024.
6. Brewer P.A., Lynch K. Stimulation-associated changes in frog neuromuscular junctions. A quantitative ultrastructural comparison of rapid-frozen and chemically fixed nerve terminals. Neuroscience 1986, 17:881-895.
7. Bruna J., Udina E., Alé A., Vilches J.J., Vynckier A., Monbaliu J., Silverman L., Navarro X. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp. Neurol. 2010, 223:599-608.
8. Carozzi V.A., Canta A., Oggioni N., Sala B., Chiorazzi A., Meregalli C., Bossi M., Marmiroli P., Cavaletti G. Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. Exp. Neurol. 2010, 226:301-309.
9. Cata J.P., Weng H.R., Lee B.N., Reubgen J.M., Dougherty P.M. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol. 2006, 72:151-169.
10. Cata J.P., Weng H.R., Burton A.W., Villareal H., Giralt S., Dougherty P.M. Quantitative sensory findings in patients with bortezomib-induced pain. J. Pain 2007, 8:296-306.
11. Cavaletti G., Jakubowiak A.J. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk. Lymphoma 2010, 51:1178-1187.
12. Cavaletti G., Gilardini A., Canta A., Rigamonti L., Rodriguez-Menendez V., Ceresa C., Marmiroli P., Bossi M., Oggioni N., D'Incalci M., De Coster R. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp. Neurol. 2007, 204:317-325.
13. Chen D., Frezza M., Schmitt S., Kanwar J.P., Dou Q. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets 2011, 11:239-253.
14. Chen Z., Janes K., Chen C., Doyle T., Bryant L., Tosh D.K., Jacobson K.A., Salvemini D. Controlling murine and rat chronic pain through A3 adenosine receptor activation. FASEB J. 2012, 26:1855-1865.
15. Chowdhury S.K., Smith D.R., Fernyhough P. The role of aberrant mitochondrial bioenergetics in diabetic neuropathy. Neurobiol. Dis. 2012, 10.1016/j.nbd.2012.03.016.
16. Corso A., Mangiacavalli S., Varettoni M., Pascutto C., Zappasodi P., Lazzarino M. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk. Res. 2010, 34:471-474.
17. Denlinger C.E., Rundall B.K., Jones D.R. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J. Thorac. Cardiovasc. Surg. 2004, 128:740-748.
18. Devor M., Govrin-Lippmann R., Frank I., Raber P. Proliferation of primary sensory neurons in adult rat dorsal root ganglion and the kinetics of retrograde cell loss after sciatic nerve section. Somatosens. Res. 1985, 3:139-167.
19. Dougherty P.M., Cata J.P., Cordella J.V., Burton A., Weng H.R. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004, 109:132-142.
20. Dougherty P.M., Cata J.P., Burton A.W., Vu K., Weng H.R. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J. Pain Symptom Manage. 2007, 33:166-179.
21. Doyle T., Chen Z., Muscoli C., Bryant L., Esposito E., Cuzzocrea S., Dagostino C., Ryerse J., Rausaria S., Kamadulski A., Neumann W.L., Salvemini D. Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. J. Neurosci. 2012, 32:6149-6160.
22. Durrant D., Liu J., Yang H.S., Lee R.M. The bortezomib-induced mitochondrial damage is mediated by accumulation of active protein kinase C-delta. Biochem. Biophys. Res. Commun. 2004, 321:905-908.
23. Flatters S.J.L., Bennett G.J. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 2004, 109:150-161.
24. Flatters S.J.L., Bennett G.J. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction. Pain 2006, 122:247-257.
25. Flatters S.J.L., Xiao W.H., Bennett G.J. Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful neuropathy. Neurosci. Lett. 2006, 397:219-223.
26. Giannoccaro M.P., Donadio V., Gomis Pèrez C., Borsini W., Di Stasi V., Liguori R. Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study. Neurol. Sci. 2011, 32:361-363.
27. Gilardini A., Avila R.L., Oggioni N., Rodriguez-Menendez V., Bossi M., Canta A., Cavaletti G., Kirschner D.A. Myelin structure is unaltered in chemotherapy-induced peripheral neuropathy. Neurotoxicology 2012, 33:1-7. http://www.ncbi.nlm.nih.gov/pubmed/22079976.
28. Gnaiger E., Kuznetsov A.V., Schneeberger S., Seiler R., Brandacher G., Steurer W., Margreiter R. Mitochondria in the cold. Life in the cold 2000, 431-442. Springer, Berlin. G. Heldmaier, M. Klingenspor (Eds.).
29. Hargreaves K., Dubner R., Brown F., Flores C., Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32:77-88.
30. Janes K., Bryant L., Salvemini D. Scavenging peroxynitrite blocks the development of paclitaxel, oxaliplatin and bortezomib-induced neuropathic pain. Soc. Neurosci. Abstr. 806.08 2011.
31. Jin H.W., Flatters S.J.L., Xiao W.H., Mulhern H.L., Bennett G.J. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: Effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp. Neurol. 2008, 210:229-237.
32. Jin L., Tabe Y., Kojima K., Zhou Y., Pittaluga S., Konopleva M., Miida T., Raffeld M. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett. 2010, 299:161-170.
33. Kuznetsov A.V., Schneeberger S., Seiler R., Brandacher G., Mark W., Steurer W., Saks V., Usson Y., Margreiter R., Gnaiger E. Mitochondrial defects and heterogeneous cytochrome c release after cardiac cold ischemia and reperfusion. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H1633-H1641.
34. Landowski T.H., Megli C.J., Nullmeyer K.D., Lynch R.M., Dorr R.T. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res. 2005, 65:3828-3836.
35. Lanzani F., Mattavelli L., Frigeni B., Rossini F., Cammarota S., Petrò D., Jann S., Cavaletti G. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J. Peripher. Nerv. Syst. 2008, 13:267-274.
36. Ling Y.H., Liebes L., Zou Y., Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J. Biol. Chem. 2003, 278:33714-33723.
37. Loprinzi C.L., Reeves B.N., Dakhil S.R., Sloan J.A., Wolf S.L., Burger K.N., Kamal A., Lindqwister N.A., Soori G.S., Jaslowski A.J., Novotny P.J., Lachance D.H. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J. Clin. Oncol. 2011, 29:1472-1478.
38. Meregalli C., Canta A., Carozzi V.A., Chiorazzi A., Oggioni N., Gilardini A., Ceresa C., Avezza F., Crippa L., Marmiroli P., Cavaletti G. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur. J. Pain 2010, 14:343-350.
39. Meyer L., Patte-Mensah C., Taleb O., Mensah-Nyagan A.G. Allopregnanolone prevents and suppresses oxaliplatin-evoked painful neuropathy: multi-parametric assessment and direct evidence. Pain 2011, 152:170-181. http://www.ncbi.nlm.nih.gov/pubmed/21071147.
40. Miranda-Massari J.R., Gonzalez M.J., Jimenez F.J., Allende-Vigo M.Z., Duconge J. Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. Curr. Clin. Pharmacol. 2011, 6:260-273.
41. Naumann I., Kappler R., von Schweinitz D., Debatin K.M., Fulda S. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. Clin. Cancer Res. 2011, 17:3204-3218.
42. Paice J.A. Chronic treatment-related pain in cancer survivors. Pain 2010, 152(3 Suppl.):S84-S89.
43. Pietrangeli A., Leandri M., Terzoli E., Jandolo B., Garufi C. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur. Neurol. 2006, 56:13-16.
44. Polomano R.C., Mannes A.J., Clark U.S., Bennett G.J. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 2001, 94:293-304.
45. Puchovicz M.A., Varnes M.E., Cohen B.H., Frieman N.R., Kerr D.S., Hoppel C.L. Oxidative phosphorylation analysis: assessing the integrated functional activity of human skeletal muscle mitochondria-case studies. Mitochondrion 2004, 4:377-385.
46. Quasthoff S., Hartung H.P. Chemotherapy-induced peripheral neuropathy. J. Neurol. 2002, 249:9-17.
47. Rasmussen U.F., Rasmussen H.N. Human quadriceps muscle mitochondria: a functional characterization. Mol. Cell. Biochem. 2000, 208:37-44.
48. Siau C., Xiao W.H., Bennett G.J. Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp. Neurol. 2006, 201:507-514.
49. Stephens F.B., Constantin-Teodosiu D., Greenhaff P.L. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J. Physiol. 2007, 581:431-444.
50. Swett J.E., Wikholm R.P., Blanks R.H.I., Swett A.L., Conley L.C. Motoneurons of the rat sciatic nerve. Exp. Neurol. 1986, 93:227-252.
51. Swett J.E., Torigoe Y., Elie V.R., Bourassa C.M., Miller P.G. Sensory neurons of the rat sciatic nerve. Exp. Neurol. 1991, 114:82-103.
52. Tsujino H., Kondo E., Fukuoka T., Dai Y., Tokunaga A., Miki K., Yonenobu K., Ochi T., Noguchi K. Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: a novel neuronal marker of nerve injury. Mol. Cell. Neurosci. 2000, 15:170-182.
53. Unterkircher T., Cristofanon S., Vellanki S.H., Nonnenmacher L., Karpel-Massler G., Wirtz C.R., Debatin K.M., Fulda S. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin. Cancer Res. 2011, 17:4019-4030.
54. Windebank A.J., Grisold W. Chemotherapy-induced neuropathy. J. Peripher. Nerv. Syst. 2008, 13:27-46.
55. Xiao W.H., Bennett G.J. Chemotherapy-evoked neuropathic pain: abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine. Pain 2008, 135:262-270.
56. Xiao W.H., Bennett G.J. Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain 2012, 153(3):704-709. (Mar).
57. Xiao W.H., Zheng F.Y., Bennett G.J., Bordet T., Pruss R.M. Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel. Pain 2009, 147:202-209.
58. Xiao W.H., Zheng H., Zheng F.Y., Nuydens R., Meert T.F., Bennett G.J. Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy. Neuroscience 2011, 199:461-469.
59. Xiao W.H., Zheng H., Bennett G.J. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 2012, 203:194-206.
60. Zheng H., Xiao W.H., Bennett G.J. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp. Neurol. 2011, 232:154-161.
61. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.